Pinion Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Pinion Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-475	Closed	-$212K	–	218
2026 Q1	$212K	Sell	475 -77	-14%	-$35.9K	0.05%	169
2025 Q4	$250K	Sell	552 -78	-12%	-$33.6K	0.06%	151
2025 Q3	$265K	Sell	630 -42	-6%	-$17.6K	0.07%	145
2025 Q2	$299K	Sell	672 -1	-0.1%	-$461	0.1%	133
2025 Q1	$326K	Buy	673 +46	+7%	+$21.4K	0.07%	117
2024 Q4	$252K	Sell	627 -208	-25%	-$96.4K	0.1%	135
2024 Q3	$388K	Buy	835 +253	+43%	+$122K	0.16%	113
2024 Q2	$273K	Buy	+582	New	+$253K	0.14%	125

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Pinion Investment Advisors's VRTX Position: Q2 2026 in Review

Pinion Investment Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 475 shares — an estimated $212K sold.

Pinion Investment Advisors first reported a position in VRTX in Q2 2024 and held it in 8 quarters. The position peaked at $388K in Q3 2024. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Pinion Investment Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Pinion Investment Advisors sold 475 Vertex Pharmaceuticals shares in Q2 2026, an estimated $212K.
Pinion Investment Advisors first reported a position in Vertex Pharmaceuticals in Q2 2024 and held it in 8 quarters.
Pinion Investment Advisors's Vertex Pharmaceuticals position peaked at $388K in Q3 2024.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Pinion Investment Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.